rs,
Corporate Services,National Stock Exchange of India Ltd.,BSE Ltd., Plot No. C/1, G Block,P. J. Towers, Dalal Street, Bandra Kurla Complex,Fort, Mumbai – 400 001Bandra (E), Mumbai – 400 051Ref: Scrip Code
6.9%
ming to our results, FY26 reflected a clear improvement in our operating performance. Revenue grew 6.9% year-on-year, supported by growth in non-GPL business of 13%, which resulted in EBITDA growth of 1
13%
operating performance. Revenue grew 6.9% year-on-year, supported by growth in non-GPL business of 13%, which resulted in EBITDA growth of 19.6%. Encouragingly, the CDMO business delivered the turnarou
19.6%
% year-on-year, supported by growth in non-GPL business of 13%, which resulted in EBITDA growth of 19.6%. Encouragingly, the CDMO business delivered the turnaround we had planned in the second half, clos
18%
he CDMO business delivered the turnaround we had planned in the second half, closing the year with 18% YoY growth. We also witnessed healthy momentum across key geographies like India, Europe, ROW, Jap
4.9%
across key geographies like India, Europe, ROW, Japan and LATAM, while the GPL business de-grew by 4.9%. For FY27, we remain confident of delivering high single-digit revenue growth, with margins sustai
30%
, we remain confident of delivering high single-digit revenue growth, with margins sustained above 30%, supported by improving operating leverage and a rising contribution from new products.” REVENUE (
2.4%
ting leverage and a rising contribution from new products.” REVENUE ( I N ₹ M I L L I ON ) 6,891 2.4% QoQ 6.1% YoY EBITDA ( I N ₹ M I L L I ON ) 2,373 -3.2% QoQ 13.8% YoY PAT ( I N ₹ M I L L
6.1%
e and a rising contribution from new products.” REVENUE ( I N ₹ M I L L I ON ) 6,891 2.4% QoQ 6.1% YoY EBITDA ( I N ₹ M I L L I ON ) 2,373 -3.2% QoQ 13.8% YoY PAT ( I N ₹ M I L L I ON ) 1,62
3.2%
REVENUE ( I N ₹ M I L L I ON ) 6,891 2.4% QoQ 6.1% YoY EBITDA ( I N ₹ M I L L I ON ) 2,373 -3.2% QoQ 13.8% YoY PAT ( I N ₹ M I L L I ON ) 1,627 8.3% QoQ 14.7% YoY GPL: Glenmark Pharmaceut
13.8%
N ₹ M I L L I ON ) 6,891 2.4% QoQ 6.1% YoY EBITDA ( I N ₹ M I L L I ON ) 2,373 -3.2% QoQ 13.8% YoY PAT ( I N ₹ M I L L I ON ) 1,627 8.3% QoQ 14.7% YoY GPL: Glenmark Pharmaceuticals Ltd. •
8.3%
Y EBITDA ( I N ₹ M I L L I ON ) 2,373 -3.2% QoQ 13.8% YoY PAT ( I N ₹ M I L L I ON ) 1,627 8.3% QoQ 14.7% YoY GPL: Glenmark Pharmaceuticals Ltd. • Alivus reported revenue from operations of ₹